<DOC>
	<DOCNO>NCT00356096</DOCNO>
	<brief_summary>The primary objective study determine efficacy pramipexole 0.125 mg 0.75 mg daily versus placebo RLS symptom associate mood disturbance depressive symptom , 12 week treatment</brief_summary>
	<brief_title>Phase IV Trial With Pramipexole Evaluate Safety Efficacy Patients With RLS Associated With Mood Disturbances</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Written inform consent consistent ICHGCP local IRB/IEC requirement obtain prior study procedure perform ability willingness comply study treatment regimen attend study assessment . 2 . Male female outpatient age 1880 year . 3 . Diagnosis idiopathic RLS accord clinical RLS criterion IRLSSG [ P0303355 ] . All four criterion must present fulfil diagnosis RLS : An urge move leg , usually accompany cause uncomfortable unpleasant sensation leg . ( Sometimes urge move present without uncomfortable sensation sometimes arm body part involve addition leg ) The urge move unpleasant sensation begin worsen period rest inactivity lie sit The urge move unpleasant sensation partially totally relieved movement , walk stretch , least long activity continue The urge move unpleasant sensation worse even night day occur even night . ( When symptom severe , worsen night may noticeable must previously present ) . 4 . RLS symptoms present least 2 3 day per week last 3 month prior baseline ( Visit 2 ) . 5 . In addition follow must demonstrate Visit 2 ( baseline ) : IRLS total score &gt; 15 A score &gt; =2 item 10 IRLS rating scale 1 . Women childbearing potential use adequate method contraception 2 . Any woman childbearing potential negative pregnancy test screen 3 . Breastfeeding woman 4 . Concomitant previous pharmacologic therapy RLS 5 . All treatment less 14 day baseline concomitant treatment medication dietary supplement , could significantly influence RLS symptom 6 . Withdrawal symptoms medication must present baseline 7 . Previous pramipexole nonresponders indication RLS . 8 . Hypersensitivity pramipexole component investigational product 9 . Diagnosis diabetes mellitus require insulin 10 . Any following laboratory result screen : clinically significant abnormality investigatos discretion ; Hb low limit normal 11 . Clinically significant renal disease screen 12 . Clinically significant hepatic disease screen 13 . Serum ferritin &lt; 10 ng/mL screening . 14 . History of/or malignant melanoma . 15 . History of/or clinically significant vision abnormality 16 . History of/or sleep disorder 17 . History of/or major depressive disorder psychotic disorder , mental disorder present Axis I psychiatric disorder accord DSM IV require medical therapy , BDIII total score &gt; 28 18 . History of/or clinical sign suicidal behaviour , suicide ideation acute suicidal tendency accord investigator opinion 19 . History of/or alcohol abuse drug addiction within last 2 year screen 20 . Patients shiftworkschedule otherwise unable follow regular sleepwake cycle 21 . Participation investigational drug study within one month prior start study 22 . Patients clinically significant condition opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>